Amgen Shares Fall 1.22% with $690M Volume Ranking 159th Despite Positive ASCEND Trial Data

. 8, 2025, , ranking 159th in the market. The biotech giant announced preliminary results from the ASCEND study of rocatinlimab, an experimental T-cell rebalancing therapy for moderate-to-severe atopic dermatitis. The Phase 3 trial, , showed sustained therapeutic benefits at one year, with low adverse event rates and potential for extended dosing intervals. The data reinforced Amgen’s focus on addressing unmet needs in chronic inflammatory diseases.

The study highlighted rocatinlimab’s long-term safety profile, with common side effects including and headaches. . Amgen and Kyowa Kirin emphasized the therapy’s potential to reduce treatment frequency, offering a more convenient option for patients. The companies plan to share full findings at a future medical conference or in a peer-reviewed journal.

The partnership between Amgen and Kyowa Kirin remains central to rocatinlimab’s development, with Amgen leading global commercialization efforts. The drug’s mechanism targeting positions it as a novel approach in dermatology, potentially differentiating it from existing therapies. Analysts noted the study’s alignment with Amgen’s broader strategy to expand its pipeline in inflammatory diseases, though market reaction to the stock’s decline suggests cautious investor sentiment ahead of regulatory and commercial milestones.

For the back-test, . stocks by trading volume, using next-day open prices for entry and same-day close for exit. Key metrics include CAGR, volatility, , and maximum drawdown, , 2022, to the latest trading day. The framework assumes no transaction costs and equal weighting. Final execution requires confirmation of parameters such as weighting schemes or adjustments to holding periods.